1
Home
Companies

Minerva Neurosciences

#8308

Rank

$254.02M

Marketcap

US United States

Country

Minerva Neurosciences
Leadership team

Mr. Frederick W. Ahlholm CPA, CPA (Sr. VP, CFO & Sec.)

Dr. Remy Luthringer Ph.D. (Exec. Chairman & CEO)

Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA (Pres)

Products/ Services
Biopharma, Biotechnology, Health Care, Neuroscience
Headquarters
Cambridge, Massachusetts, United States
Established
2007
Company Registration
SEC CIK number: 0001598646
Traded as
NERV
Social Media
URL
https://www.minervaneurosciences.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
History

Minerva Neurosciences was founded in 2007 as a privately held pharmaceutical and biopharmaceutical company focused on the development and commercialization of product candidates for the treatment of central nervous system (CNS) disorders. In 2017, the company achieved their initial public offering, followed in 2018 by the acquisition of two Phase 2-stage chemical entities, roluperidone and MIN-101, expanding their pipeline and therapy area focus.

Mission
Our mission is to offer efficacious and safe treatments to those suffering from CNS disorders, representing a true medical need.
Vision
We are committed to becoming a leader in the development of innovative and novel products for the treatment of CNS disorders.
Key Team

Mr. William B. Boni (VP of Investor Relations & Corp. Communications)

Prof. Michael Davidson M.D. (Chief Medical Officer)

Dr. Ramana Kuchibhatla Ph.D. (Sr. VP and Head of R&D)

Mr. Joseph Reilly (Sr. VP & COO)

Recognition and Awards
Minerva Neurosciences has been recognized by the Massachusetts Biotechnology Council’s Award for Corporate Excellence, among other achievements.
References

https://en.wikipedia.org/wiki/MIN-117

https://in.investing.com/equities/minerva-neu

https://finance.yahoo.com/quote/NERV/profile?p=NERV

https://www.crunchbase.com/organization/minerva-neuroscience

https://companiesmarketcap.com/

https://www.minervaneurosciences.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Minerva Neurosciences
Leadership team

Mr. Frederick W. Ahlholm CPA, CPA (Sr. VP, CFO & Sec.)

Dr. Remy Luthringer Ph.D. (Exec. Chairman & CEO)

Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA (Pres)

Products/ Services
Biopharma, Biotechnology, Health Care, Neuroscience
Headquarters
Cambridge, Massachusetts, United States
Established
2007
Company Registration
SEC CIK number: 0001598646
Traded as
NERV
Social Media
URL
https://www.minervaneurosciences.com